Trastuzumab Emtansine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Trastuzumab Emtansine
Trastuzumab Emtansine: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidate indications for Trastuzumab Emtansine. Every candidate that can be traced to a source is already a known use. There is currently no new predicted indication for this drug.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 4 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| progesterone-receptor positive breast cancer | breast cancer |
| normal breast-like subtype of breast carcinoma | breast cancer |
| progesterone-receptor negative breast cancer | breast cancer |
| breast tumor luminal A or B | breast cancer |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02412365 | KADCYLA | Valid | |
| 02473224 | KADCYLA | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antibody-drug conjugate (HER2-targeted antibody linked to a cytotoxic microtubule inhibitor, DM1) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; typically blood counts, liver function and cardiac function |
| Handling Protection | Follow institutional cytotoxic drug handling regulations |
Safety Considerations
Drug Interactions: The interaction query returned 100 records. The main ones shown below are mostly anticoagulant, antiplatelet and related agents.
- Major: acetylsalicylic acid, deferasirox, abciximab, apixaban, argatroban, betrixaban, bivalirudin, cangrelor, caplacizumab, cilostazol
- Moderate: clarithromycin, dexfenfluramine, fenfluramine, metronidazole, naltrexone, rosuvastatin, sibutramine, simvastatin, tinidazole, cobicistat
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.